Ortrip

Quick links to important sections

Ortrip

Method of action: Antidepressant, Psychoanaleptics

Treatment option: Depression

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ortrip

Property Description
Active ingredient Nortriptyline Hydrochloride
Form Oral Capsule or Oral Solution
Pharmacological class Tricyclic Antidepressant (TCA)
Common purpose Modulating nerve signals and stabilizing mood
Origin Synthetic Compound

What Type of Medicine is Ortrip?

Ortrip is a brand name for a medication whose active component is Nortriptyline Hydrochloride. It is classified as a prescription-only drug and belongs to the pharmacological class of Tricyclic Antidepressants (TCA), specifically identified as a first-generation antidepressant. The active substance is a synthetic compound, structurally defined as a secondary amine that is derived from the core Dibenzocycloheptadiene chemical structure.

The active ingredient, Nortriptyline, is considered a well-established agent for regulating chemical pathways within the central nervous system. This medicine is clinically recognized for its therapeutic profile in managing conditions where chemical balance in the brain is disrupted.


Ortrip's General Purpose and Form

The general purpose of Ortrip is to modulate nerve signaling by influencing the availability of specific chemical messengers. The medication is designed for oral administration and is typically dispensed as an oral capsule or an oral solution. This availability in two distinct forms is a key feature, allowing healthcare providers to tailor administration based on patient needs, such as prescribing the oral solution for patients who have difficulty swallowing capsules.

Its primary mechanism principle involves acting as a reuptake inhibitor of key chemical messengers, notably Norepinephrine and, to a lesser degree, Serotonin, thereby increasing their concentration between nerve cells. This function makes it useful for promoting emotional stability and regulating abnormal signals transmitted through the nervous system. For instance, this medication is typically used in scenarios requiring the stabilization of mood, demonstrating a foundational benefit in supporting overall neurochemical well-being.

Regulatory References

  1. DrugBank

What side effects are possible with Ortrip?

The official safety profile of Ortrip, whose active ingredient is Nortriptyline Hydrochloride, is detailed in regulatory documents by categories of frequency and affected body systems. This structure is used by government health agencies to communicate the full range of documented risks.

Adverse Reaction Scope

The most frequently reported effects (classified as Very Common or Common) often relate to anticholinergic activity and the central nervous system. These include dry mouth, constipation, blurred vision, tremor, headache, and orthostatic hypotension (dizziness upon standing). The documented effects are grouped into System-Organ Classes such as Cardiac Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling describes several serious adverse reactions, including the potential for Cardiac Arrhythmias, Myocardial Infarction, and Seizures. A Boxed Warning is in place regarding the increased risk of suicidal ideation and behavior in young adults (up to age 24), particularly during the initial months of therapy or when dosages are adjusted.

Safety limitations explicitly stated in regulatory texts include its contraindication during the acute recovery period following a Myocardial Infarction and when used concurrently with Monoamine Oxidase Inhibitors (MAOIs). Additionally, use requires caution in patients with a history of glaucoma or urinary retention.

Population-Specific Notes: Older adults may be more susceptible to certain effects, such as confusion, agitation, and orthostatic hypotension, compared to younger adults.

Connection to the Official Safety Profile

This collection of safety information—from common physical effects to rare serious risks—establishes the mandatory regulatory framework for the drug. The profile is structured to define the totality of known risks and the high-level safety constraints based on the official evidence reviewed by health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Domain Official Regulatory Statements
Manifestations and Outcomes Overdose symptoms often appear rapidly, typically within six hours of ingestion, and may include severe drowsiness, agitation, confusion, seizures, or coma. Life-threatening toxicity primarily involves the cardiovascular system, potentially resulting in profound hypotension and severe ventricular dysrhythmias. Anticholinergic signs, such as mydriasis (dilated pupils) and urinary retention, may also be present.
Mandatory Emergency Action Any suspected overdose requires immediate medical attention. Contact emergency services right away and seek hospital monitoring as soon soon as possible, as rapid deterioration is possible. All symptomatic patients require admission to a monitored setting, such as an Intensive Care Unit (ICU).
Key Severity Indicator and Management Continuous ECG monitoring is mandatory to assess for cardiotoxicity. A maximal limb-lead QRS duration of ge 0.10 seconds is the documented best indicator of overdose severity. Management is symptomatic and supportive, including securing the airway, administering activated charcoal for recent ingestions, and using intravenous sodium bicarbonate to manage QRS prolongation and arrhythmias.
Specific Risk Factors Concurrent use with a Monoamine Oxidase (MAO) inhibitor is contraindicated and has resulted in severe convulsions and fatalities. Excessive alcohol consumption also increases the danger of overdosage, according to official regulatory labeling.

Therapeutic Uses of Ortrip

What Ortrip Treats: Main Uses and Benefits

Ortrip is commonly used to help manage symptoms across multiple therapeutic domains. It is considered relevant for easing distress in conditions associated with heightened symptoms, including Major Depressive Disorder, chronic neuropathic pain (such as diabetic neuropathy and postherpetic neuralgia), and for managing the frequency of recurrent migraine manifestations.


Symptom Management and Functional Support

Ortrip is applied in addressing symptom clusters that may become intense or disruptive. This medication is applied across domains where additional symptomatic support is needed, which helps ease the overall symptom burden. One patient-oriented benefit is related to pain management: “It may help improve day-to-day comfort during symptomatic periods, including support for managing symptoms that interfere with daily functioning.”

For mood, this symptomatic support contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations, generally supporting general well-being during symptomatic phases. Furthermore, it is considered relevant when supportive symptom management is appropriate in contexts like playing a role in managing symptoms within programs designed for smoking cessation.


Quick Fact: Relief for Chronic Discomfort
This medication is commonly used to address symptoms of chronic neuropathic pain (nerve-driven pain) and symptoms related to Major Depressive Disorder.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Ortrip (Nortriptyline)

This section outlines population eligibility and restrictions for using nortriptyline, based strictly on official government regulatory labeling.

Category Regulatory Status
Absolute Prohibitions (Contraindications) The medicine must not be used by patients with a known hypersensitivity to nortriptyline, during the acute recovery period following myocardial infarction, or concurrently with, or within 14 days of discontinuing, a Monoamine Oxidase (MAO) Inhibitor. Use is also contraindicated in patients with a known or suspected diagnosis of Brugada Syndrome.
Age Restriction Safety and efficacy have not been established in the pediatric population (children and adolescents under 18); therefore, use is generally not approved or not recommended. Young adults (ages 18–24) require close monitoring due to increased risk of suicidal ideation.
Conditional/Restricted Use Use requires close supervision in patients with a history of cardiovascular disease or seizures as the drug can affect heart conduction and lower the seizure threshold. It must be used with great caution in patients with angle-closure glaucoma or a history of urinary retention.
Reproductive Status Safe use has not been established during pregnancy or lactation (breastfeeding); use must be weighed against possible hazards.

Eligibility for nortriptyline is determined by avoiding absolute contraindications and ensuring that pre-existing medical conditions (comorbidities) that necessitate caution are carefully managed.

What should I know about interactions with other medicines?

Ortrip Interactions with other medicines and products

Contraindicated Combinations

Monoamine Oxidase (MAO) Inhibitors are strictly contraindicated due to the risk of severe or life-threatening reactions, including Serotonin Syndrome, hyper-pyretic crises, and convulsions. This includes MAOIs used for psychiatric conditions and certain other agents with MAOI activity, such as linezolid and intravenous methylene blue. A mandatory two-week washout period is required when switching between Ortrip and an MAOI: Ortrip must not be started within 14 days of stopping an MAOI, and vice versa.

Other Significant Interactions

  • Serotonergic Drugs: Use with other serotonergic medicines (e.g., triptans, fentanyl, lithium, buspirone, tryptophan, St. John’s Wort) requires caution, as the combination increases the risk of Serotonin Syndrome.
  • Central Nervous System (CNS) Depressants: Ortrip will increase the effects of alcohol and other CNS depressants, potentially leading to increased sedation and impaired performance. Alcohol use should be avoided.
  • CYP2D6 Inhibitors: Ortrip is metabolized by the enzyme CYP2D6. Concomitant use with strong inhibitors of this enzyme, such as quinidine or cimetidine, can significantly increase the concentration of Ortrip in the body, potentially leading to increased adverse effects. Conversely, tobacco smoking may increase Ortrip’s clearance, potentially reducing efficacy.

Mechanism of Action

Ortrip's pharmacological action is defined by a pleiotropic mechanism that modulates both the chemical balance and the electrical signaling of the nervous system. The primary domain involves inhibiting the Norepinephrine Transporter (NET) and, to a lesser degree, the Serotonin Transporter (SERT). By blocking the reuptake of Norepinephrine (NE) and Serotonin (5-HT), the drug increases their concentration in the synaptic cleft. This sustained neurochemical presence initiates a delayed cascade of neuroplastic changes, which gradually influences central signaling pathways over time.

A secondary mechanistic domain is the direct blockade of Voltage-Gated Sodium ( Na^+) Channels, which stabilizes the nerve membrane and dampens the ability of nerve cells to transmit electrical impulses. This action contributes to the physiological modulation of nociceptive signal traffic. Furthermore, Ortrip acts as an antagonist at several non-monoamine targets, including Histamine ( H1) and Muscarinic Acetylcholine ( mACh) Receptors, influencing collateral systems such as arousal and autonomic output. This multiple-target profile establishes a mechanism-dependent signature inherent to the molecule's structure.

Dosage and Administration Information

How to Use Ortrip

This section explains the general principles and administration patterns for Ortrip (Nortriptyline).


Administration Scope

Feature Instruction Summary
Route of administration Oral (by mouth)
Dosing schedule The total daily dosage may be administered in divided doses or as a single dose, typically once a day at bedtime, as an alternate regimen.
Starting & Titration Treatment must begin at a low dosage level and be gradually increased as required by professional judgment.
Maximum Dose The daily dosage should not exceed 150 mg for adults.
Administration Timing Can be taken with or without food.
Preparation The oral solution must be measured using a special measuring device to ensure dosage accuracy.

Population-Specific Use and Protocol

Feature Instruction Summary
Older Adults A lower starting dose (e.g., 10 mg daily) and maintenance range, such as 30 mg to 50 mg per day, is generally recommended for older patients.
Discontinuation Treatment must be discontinued gradually via dose reduction; abrupt cessation is not recommended.
Dose Monitoring When the total daily dose exceeds 100 mg, monitoring of the drug's plasma levels is required to ensure the dose remains within the optimal therapeutic range.

The usage protocol is structured around a mandatory titration process and allows for flexibility in the daily timing (divided or single dose) while strictly limiting the maximum daily intake. The instructions define specific population-based adjustments and mandate the procedural steps for discontinuation, ensuring adherence to the standardized method of administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Ortrip

Ortrip (Nortriptyline) has been evaluated across decades through various types of formal research, including randomized controlled trials (RCTs), systematic reviews, and meta-analyses. The findings from these studies contribute to the scientific understanding of its profile as described by the research, primarily by exploring how symptoms are measured and change over defined time intervals. Research generally focuses on specific outcomes reflecting functional imbalance or episodes of heightened symptom activity.


Evidence related to Research for Major Depressive Disorder

Research exploring outcomes related to Major Depressive Disorder (MDD) has primarily utilized short-term (6–8 weeks) and intermediate-term (up to 6 months) randomized controlled trials. Studies monitored the change in the severity of depressive symptoms using standardized clinical scales and tracked the proportion of participants reported to meet criteria for a clinical response or remission. What remains uncertain is that many foundational comparative studies are older, and limited information is available regarding long-term outcomes related to functional recovery over periods exceeding six months.

Evidence related to Research Exploring Chronic Neuropathic Pain Symptoms

For chronic nerve-driven pain, studies explored how symptoms are measured in short- to medium-term (3 to 12 weeks) randomized controlled trials and subsequent systematic reviews. The research focused on patient-reported outcomes describing discomfort, such as changes in pain intensity scores. Findings were mixed and not fully consistent across all different types of nerve pain conditions studied. Evidence is often limited due to small participant numbers in individual trials, and data on sustained measurements over time are not fully established.

What Research Gaps and Uncertainties Remain

Research highlights that evidence quality varies across studies. Comparative evidence against many modern treatments is often lacking. For conditions characterized by fluctuating manifestations, the follow-up durations were limited, leaving long-term effects not fully established. Furthermore, data for complex or specific patient groups, such as some geriatric populations or those with complex comorbid conditions, remains insufficient.

Key Studies & References

  1. Nortriptyline for Migraine and Headaches (Clinical Guidance/Patient Leaflet)

Frequently Asked Questions (FAQ)

Common questions about Ortrip (FAQ)


Q: Is Ortrip a type of painkiller?

A: Ortrip is officially classified as a Tricyclic Antidepressant (TCA) and is primarily approved for managing Major Depressive Disorder. Due to its mechanism involving nerve signal regulation, it is also a subject of research and clinical use for managing symptoms of certain types of chronic nerve-related discomfort.


Q: How quickly does Ortrip start working?

A: Studies and official information indicate that Ortrip's full therapeutic effect is not immediate. The pharmacological action involves a delayed cascade of changes in the nervous system. While some initial changes may be experienced sooner by some patients, the full therapeutic benefit for conditions like depression typically takes several weeks to fully develop, as noted in clinical studies.


Q: How long do the effects of Ortrip typically last?

A: Ortrip's active ingredient has a prolonged elimination half-life, typically ranging between 16 to 38 hours. This long duration allows the total required daily dosage to be administered once daily, as established in the usage guidelines.


Q: Can Ortrip cause drowsiness or fatigue?

A: Yes. According to official product information, drowsiness, generalized weakness, and fatigue are common or frequently reported adverse reactions. These effects are related to how the medicine acts on the central nervous system.


Q: Are there any common digestive side effects from taking Ortrip?

A: Yes, constipation is one of the frequently reported side effects. Other gastrointestinal adverse reactions noted in regulatory documents can include nausea, vomiting, and abdominal cramps.


Q: What should I do if I forget to take a dose of Ortrip?

A: If a dose is missed, regulatory guidance generally suggests taking it as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose is generally skipped instead. It is advised not to take a double or extra dose to compensate for the one you missed.


Q: Can Ortrip be taken with vitamins or supplements?

A: Caution is advised when combining Ortrip with certain supplements. Regulatory documents specifically warn against combining it with the herbal supplement St. John’s Wort, as this can increase the risk of serious side effects. It is important for patients to share a complete list of all supplements and herbal products with their healthcare provider, as some may affect how Ortrip works.


Q: How long can I safely take Ortrip for?

A: Regulatory documents indicate that clinical trials primarily track outcomes over periods up to six months. Information related to the safety and functional recovery for treatment periods exceeding six months is more limited, as is the case with many older medications.


Q: Is Ortrip suitable for long-term use?

A: Official documentation does not define a maximum duration of use. Decisions regarding extended use are based on individual medical assessment. Studies on this medicine have primarily focused on treatment periods of six months or less, and information on effects sustained over longer durations is limited in the current regulatory literature.


Q: What's the difference between Ortrip and other similar cold/allergy medicines?

A: Ortrip is a prescription-only Tricyclic Antidepressant (TCA) and is fundamentally different from typical over-the-counter cold or allergy medicines. However, it does possess an action on the Histamine ( H1) receptor, which is an action it shares with some common allergy medications.


Q: Is Ortrip the same as Claritin or Zyrtec?

A: No, Ortrip is not the same as Claritin or Zyrtec. Ortrip is classified as a Tricyclic Antidepressant (TCA) and is a prescription-only medication, while Claritin and Zyrtec are typically classified as second-generation antihistamines, which may be available over-the-counter.


Q: What are the most common reasons people stop taking Ortrip?

A: People who discontinue treatment often do so due to the most common adverse effects. These frequently include side effects such as dry mouth, drowsiness, constipation, and dizziness, which are widely documented in the official safety profile of the drug.


Q: Does Ortrip have a risk of dependency?

A: While the medicine is generally not associated with physical dependency, regulatory documents state that treatment requires gradual discontinuation via dose reduction to avoid withdrawal symptoms. Abruptly stopping the medication is not recommended.


Q: Are there any specific foods to avoid while on Ortrip?

A: Regulatory warnings specifically advise that alcohol use should be avoided while taking Ortrip, as it can increase the sedative effects. There are no specific warnings regarding common foods or food groups.


Q: Can Ortrip change your mood or cause irritability?

A: Yes, official warnings mention that changes in mental state, behavior, or mood can occur. This includes a boxed warning about the increased risk of suicidal thoughts and behaviors in young adults, and symptoms like agitation or anxiety can also occur, especially during the initial months of therapy.


Q: Can Ortrip be crushed or split?

A: Ortrip is available as both an oral capsule and an oral solution formulation. The oral capsule formulation is typically intended to be swallowed whole. The oral solution is available to accommodate those who have difficulty swallowing capsules.


Q: Are there different strengths or formulations of Ortrip available?

A: Yes, regulatory information lists Ortrip as being available in both an oral capsule and an oral solution formulation. The capsules are typically available in multiple strengths, such as 10 mg, 25 mg, 50 mg, and 75 mg.


Q: Can I take Ortrip if I have high blood pressure?

A: Regulatory documents state that use of Ortrip requires close supervision in patients with a history of cardiovascular disease or a heart condition, as the drug can affect heart conduction and blood pressure. Furthermore, a common side effect is orthostatic hypotension, which is a drop in blood pressure that causes dizziness upon standing.


Q: Does Ortrip interact with any heart medications?

A: Yes, significant interactions are possible. Ortrip is absolutely contraindicated (must not be used) during the acute recovery period following a heart attack. Additionally, because it is broken down in the liver by the CYP2D6 enzyme, combining it with other strong CYP2D6 inhibitors (which can include some heart medications) can increase the concentration of Ortrip in the body, potentially increasing adverse effects.

How should Ortrip be stored and disposed of?

Storage and Disposal Requirements

Ortrip (nortriptyline hydrochloride) must be stored strictly according to governmental regulatory standards to ensure product stability and safety.

Storage Conditions

Detail Requirement
Temperature Store at Controlled Room Temperature (20 to 25 C / 68 to 77 F).
Protection Keep in a tight, light-resistant container.
Child Safety Must be stored out of the reach of children.

Disposal Instructions

Unused or expired medication should be discarded following established federal guidelines. The preferred method is using a community drug take-back program. If a program is unavailable, the medication should be mixed with an unpalatable substance and placed in a sealed container before disposal in the household trash. The product must not be flushed down the toilet unless explicitly instructed by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ortrip found in:

A-Z Index: